Effector Other Stockholder Equity vs Cash And Short Term Investments Analysis

EFTR Stock

USD 0.0002 0.00 0.00%

Effector Therapeutics financial indicator trend analysis is much more than just examining Effector Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Effector Therapeutics is a good investment. Please check the relationship between Effector Therapeutics Other Stockholder Equity and its Cash And Short Term Investments accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Effector Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Effector Stock, please use our How to Invest in Effector Therapeutics guide.

Other Stockholder Equity vs Cash And Short Term Investments

Other Stockholder Equity vs Cash And Short Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Effector Therapeutics Other Stockholder Equity account and Cash And Short Term Investments. At this time, the significance of the direction appears to have strong relationship.

The correlation between Effector Therapeutics' Other Stockholder Equity and Cash And Short Term Investments is 0.6. Overlapping area represents the amount of variation of Other Stockholder Equity that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Effector Therapeutics, assuming nothing else is changed. The correlation between historical values of Effector Therapeutics' Other Stockholder Equity and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Stockholder Equity of Effector Therapeutics are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Other Stockholder Equity i.e., Effector Therapeutics' Other Stockholder Equity and Cash And Short Term Investments go up and down completely randomly.

Correlation Coefficient

0.6

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Other Stockholder Equity

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Effector Therapeutics balance sheet. This account contains Effector Therapeutics investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Effector Therapeutics fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Most indicators from Effector Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Effector Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Effector Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Effector Stock, please use our How to Invest in Effector Therapeutics guide.At this time, Effector Therapeutics' Issuance Of Capital Stock is relatively stable compared to the past year. As of 12/10/2025, Sales General And Administrative To Revenue is likely to grow to 3.47, though Enterprise Value Over EBITDA is likely to grow to (1.04).

	2022	2023	2024	2025 (projected)
Interest Expense	2.3M	2.9M	3.4M	2.1M
Depreciation And Amortization	53K	111K	99.9K	104.8K

Interest Expense Depreciation And Amortization

Effector Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Current Deferred Revenue	Long Term Debt	Common Stock Total Equity
Total Assets		0.71	-0.12	-0.32	0.95	0.88	-0.79	-0.84	0.3	0.41	0.94	0.33	0.92	0.82	1.0	0.77	0.99	0.6	0.23	1.0	-0.41	0.8	-0.88	-0.32	0.82	0.82
Short Long Term Debt Total	0.71		0.32	0.42	0.51	0.93	-0.68	-0.32	-0.29	0.83	0.56	0.45	0.85	0.38	0.71	0.93	0.66	0.88	-0.21	0.7	0.32	0.97	-0.61	-0.51	0.97	0.96
Other Current Liab	-0.12	0.32		0.48	-0.33	0.05	0.47	0.26	-0.26	0.14	-0.16	0.83	-0.14	-0.1	-0.13	-0.02	-0.12	0.08	-0.99	-0.13	0.46	0.23	0.5	-0.01	0.13	0.13
Total Current Liabilities	-0.32	0.42	0.48		-0.46	0.15	0.05	0.7	-0.75	0.58	-0.51	0.14	0.01	-0.43	-0.32	0.28	-0.4	0.39	-0.5	-0.32	0.99	0.3	0.25	-0.2	0.27	0.26
Total Stockholder Equity	0.95	0.51	-0.33	-0.46		0.73	-0.76	-0.87	0.5	0.17	0.89	0.17	0.83	0.9	0.95	0.65	0.94	0.37	0.42	0.95	-0.54	0.65	-0.87	-0.08	0.69	0.7
Net Tangible Assets	0.88	0.93	0.05	0.15	0.73		-0.84	-0.52	-0.16	0.77	0.73	0.33	0.98	0.56	0.88	0.95	0.83	0.88	0.05	0.87	0.05	0.95	-0.82	-0.52	0.97	0.97
Property Plant And Equipment Net	-0.79	-0.68	0.47	0.05	-0.76	-0.84		0.57	0.06	-0.64	-0.71	0.21	-0.91	-0.46	-0.8	-0.88	-0.75	-0.75	-0.56	-0.79	0.13	-0.74	0.97	0.44	-0.8	-0.8
Net Debt	-0.84	-0.32	0.26	0.7	-0.87	-0.52	0.57		-0.57	0.03	-0.95	-0.14	-0.6	-0.73	-0.84	-0.44	-0.88	-0.22	-0.37	-0.84	0.76	-0.44	0.71	0.02	-0.47	-0.48
Retained Earnings	0.3	-0.29	-0.26	-0.75	0.5	-0.16	0.06	-0.57		-0.69	0.37	0.12	-0.03	0.67	0.3	-0.24	0.35	-0.55	0.3	0.3	-0.74	-0.16	-0.14	0.45	-0.15	-0.14
Accounts Payable	0.41	0.83	0.14	0.58	0.17	0.77	-0.64	0.03	-0.69		0.26	0.11	0.69	-0.06	0.41	0.8	0.35	0.97	-0.09	0.41	0.51	0.73	-0.51	-0.78	0.75	0.73
Cash	0.94	0.56	-0.16	-0.51	0.89	0.73	-0.71	-0.95	0.37	0.26		0.24	0.79	0.71	0.94	0.64	0.97	0.49	0.28	0.94	-0.6	0.64	-0.82	-0.28	0.67	0.67
Non Current Assets Total	0.33	0.45	0.83	0.14	0.17	0.33	0.21	-0.14	0.12	0.11	0.24		0.2	0.43	0.32	0.15	0.33	0.14	-0.79	0.32	0.1	0.43	0.13	-0.05	0.35	0.36
Non Currrent Assets Other	0.92	0.85	-0.14	0.01	0.83	0.98	-0.91	-0.6	-0.03	0.69	0.79	0.2		0.63	0.92	0.94	0.88	0.82	0.24	0.92	-0.08	0.9	-0.92	-0.48	0.93	0.94
Other Assets	0.82	0.38	-0.1	-0.43	0.9	0.56	-0.46	-0.73	0.67	-0.06	0.71	0.43	0.63		0.81	0.42	0.8	0.1	0.17	0.81	-0.49	0.54	-0.61	0.15	0.54	0.56
Cash And Short Term Investments	1.0	0.71	-0.13	-0.32	0.95	0.88	-0.8	-0.84	0.3	0.41	0.94	0.32	0.92	0.81		0.77	0.99	0.6	0.25	1.0	-0.41	0.79	-0.88	-0.32	0.82	0.82
Common Stock Shares Outstanding	0.77	0.93	-0.02	0.28	0.65	0.95	-0.88	-0.44	-0.24	0.8	0.64	0.15	0.94	0.42	0.77		0.72	0.89	0.12	0.77	0.19	0.95	-0.81	-0.45	0.98	0.97
Other Current Assets	0.99	0.66	-0.12	-0.4	0.94	0.83	-0.75	-0.88	0.35	0.35	0.97	0.33	0.88	0.8	0.99	0.72		0.56	0.24	0.99	-0.49	0.74	-0.85	-0.32	0.76	0.77
Other Stockholder Equity	0.6	0.88	0.08	0.39	0.37	0.88	-0.75	-0.22	-0.55	0.97	0.49	0.14	0.82	0.1	0.6	0.89	0.56		0.0	0.6	0.3	0.82	-0.66	-0.76	0.84	0.83
Total Liab	0.23	-0.21	-0.99	-0.5	0.42	0.05	-0.56	-0.37	0.3	-0.09	0.28	-0.79	0.24	0.17	0.25	0.12	0.24	0.0		0.24	-0.5	-0.12	-0.59	-0.05	-0.03	-0.03
Total Current Assets	1.0	0.7	-0.13	-0.32	0.95	0.87	-0.79	-0.84	0.3	0.41	0.94	0.32	0.92	0.81	1.0	0.77	0.99	0.6	0.24		-0.41	0.79	-0.88	-0.32	0.82	0.82
Short Term Debt	-0.41	0.32	0.46	0.99	-0.54	0.05	0.13	0.76	-0.74	0.51	-0.6	0.1	-0.08	-0.49	-0.41	0.19	-0.49	0.3	-0.5	-0.41		0.21	0.33	-0.15	0.17	0.16
Common Stock	0.8	0.97	0.23	0.3	0.65	0.95	-0.74	-0.44	-0.16	0.73	0.64	0.43	0.9	0.54	0.79	0.95	0.74	0.82	-0.12	0.79	0.21		-0.7	-0.36	1.0	1.0
Property Plant Equipment	-0.88	-0.61	0.5	0.25	-0.87	-0.82	0.97	0.71	-0.14	-0.51	-0.82	0.13	-0.92	-0.61	-0.88	-0.81	-0.85	-0.66	-0.59	-0.88	0.33	-0.7		0.4	-0.76	-0.76
Current Deferred Revenue	-0.32	-0.51	-0.01	-0.2	-0.08	-0.52	0.44	0.02	0.45	-0.78	-0.28	-0.05	-0.48	0.15	-0.32	-0.45	-0.32	-0.76	-0.05	-0.32	-0.15	-0.36	0.4		-0.39	-0.37
Long Term Debt	0.82	0.97	0.13	0.27	0.69	0.97	-0.8	-0.47	-0.15	0.75	0.67	0.35	0.93	0.54	0.82	0.98	0.76	0.84	-0.03	0.82	0.17	1.0	-0.76	-0.39		1.0
Common Stock Total Equity	0.82	0.96	0.13	0.26	0.7	0.97	-0.8	-0.48	-0.14	0.73	0.67	0.36	0.94	0.56	0.82	0.97	0.77	0.83	-0.03	0.82	0.16	1.0	-0.76	-0.37	1.0

Click cells to compare fundamentals

Effector Therapeutics Account Relationship Matchups

Effector Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	16.7M	54.1M	29.1M	20.5M	23.6M	27.6M
Short Long Term Debt Total	13.0M	20.0M	20.3M	20.5M	23.6M	19.6M
Other Current Liab	82K	3.0M	2.9M	2.9M	3.4M	2.6M
Total Current Liabilities	8.8M	4.0M	25.1M	25.8M	29.7M	18.2M
Total Stockholder Equity	979K	17.3M	3.9M	(5.8M)	(6.7M)	(6.3M)
Property Plant And Equipment Net	126K	257K	352K	193K	173.7K	280.2K
Net Debt	(2.3M)	(29.7M)	11.6M	5.7M	6.5M	6.8M
Retained Earnings	(136.7M)	(120.9M)	(143.6M)	(179.4M)	(161.4M)	(169.5M)
Accounts Payable	347K	516K	1.5M	2.3M	2.7M	2.8M
Cash	15.2M	49.7M	8.7M	14.9M	17.1M	20.2M
Non Current Assets Total	126K	1.2M	1.1M	706K	811.9K	853.2K
Non Currrent Assets Other	(126K)	903K	711K	513K	590.0K	619.4K
Cash And Short Term Investments	15.2M	49.7M	26.3M	18.4M	21.1M	24.9M
Common Stock Shares Outstanding	598.6K	1.6M	1.6M	2.2M	2.5M	1.3M
Liabilities And Stockholders Equity	16.7M	54.1M	29.1M	20.5M	23.6M	27.6M
Other Current Assets	1.4M	3.2M	1.7M	1.4M	1.6M	1.9M
Other Stockholder Equity	4.5M	138.2M	147.5M	347.2M	399.2M	419.2M
Total Liab	148.9M	36.8M	25.2M	26.3M	23.7M	41.0M
Total Current Assets	16.6M	52.9M	28.0M	19.8M	22.8M	26.8M
Short Term Debt	6.0M	88K	20.2M	20.5M	23.6M	13.7M

Additional Tools for Effector Stock Analysis

When running Effector Therapeutics' price analysis, check to measure Effector Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Effector Therapeutics is operating at the current time. Most of Effector Therapeutics' value examination focuses on studying past and present price action to predict the probability of Effector Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Effector Therapeutics' price. Additionally, you may evaluate how the addition of Effector Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Effector Other Stockholder Equity vs Cash And Short Term Investments Analysis

Other Stockholder Equity vs Cash And Short Term Investments

Other Stockholder Equity vs Cash And Short Term Investments Correlation Analysis

Correlation Coefficient

Other Stockholder Equity

Cash And Short Term Investments

Effector Therapeutics fundamental ratios Correlations

Effector Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Effector Therapeutics fundamental ratios Accounts

Additional Tools for Effector Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Long Term Debt	+ 1.0	Common Stock
Common Stock Total Equity	+ 1.0	Common Stock
Common Stock Total Equity	+ 1.0	Long Term Debt

Total Liab	- 0.99	Other Current Liab
Cash	- 0.95	Net Debt
Property Plant Equipment	- 0.92	Non Currrent Assets Other
Non Currrent Assets Other	- 0.91	Property Plant And Equipment Net
Property Plant Equipment	- 0.88	Total Current Assets
Property Plant Equipment	- 0.88	Cash And Short Term Investments